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Abstract
Purpose The aim of the present study was to assess the long-
term tolerability and efficacy of intranasal fentanyl (INFS) in
opioid-tolerant patients with breakthrough cancer pain (BTP).
Patients andmethods A6months, observational, prospective,
cohort study design was employed to follow advanced cancer
patients with BTP receiving INFS under routine clinical prac-
tice. Eligible adult cancer patients suffering from BTP had
been prescribed INFS at effective doses. Data were collected
at T0 and at month intervals for six months. The principal
outcomes were the evaluation of possible serious adverse
effects with prolonged use of INFS, the efficacy of BTP
treatment with INFS, the quality of sleep, the rate of INFS
discontinuation, and reasons for that.
Results Seventy-five patients were surveyed. Thirty-four pa-
tients (45.3 %) had a follow-up at 3 months, and twelve
patients (16 %) were followed up at 6 months. The mean
opioid doses, expressed as oral morphine equivalents, ranged
111–180 mg/day, while the mean INFS doses were 87–
119μg. Adverse effects were reported in a minority of patients
and were considered to be associated with opioid therapy used
for background pain. The quality of sleep significantly im-
proved during the first 3–4 months. Finally, efficacy based on
a general impression regarding the efficacy of INFS was
good-excellent in most patients and statistically improved in
time up to the third month.
Conclusion The long-term use of INFS in advanced cancer
patients is effective and safe. No serious adverse effects were
found up to six months of assessment. The level of quality of
sleep and patients’ satisfaction was relatively good, consider-
ing the advanced stage of disease.
Keywords Cancer pain . Breakthrough pain . Intranasal
fentanyl . Tolerability
Introduction
Breakthrough cancer pain (BTP) is defined as a transient
exacerbation of pain that occurs on a background of otherwise
stable persistent pain [1]. BTP affects more than half of all
patients with cancer and has a substantial impact on quality of
life, including detrimental effects on activities of daily living,
sleep, social relationships, and enjoyment of life [2]. Conse-
quently, control of BTP represents an important therapeutic
goal in the care of patients with cancer. Typical episodes of
BTP are characterized by a rapid onset, short duration, and
severe intensity [3]. As a result, current treatments for BTP
primarily involve immediate-release opioids, such as mor-
phine, oxycodone, and hydromorphone. However, the
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hydrophilic nature of such opioids means that they are pri-
marily absorbed through the gut, leaving them prone to first-
pass metabolism and slow onset of action. Thus, these drugs
can take about 30 min to produce an analgesic effect, which
then lasts for about 4 h. This approach may be suitable for
treating some pain conditions with a slow onset or adminis-
tering such drugs before an expected predictable pain event.
Indeed, oral immediate-release opioids do not reach peak
activity until 30–45 min after administration [4] and are there-
fore unable to match the time–pain profile of BTP episodes.
The majority of BTP episodes require a treatment with a fast
onset of action and short duration of effect. Fentanyl is a
highly lipophilic opioid and is therefore well-suited to oral
transmucosal administration.
A range of fast-acting fentanyl formulations has been de-
veloped and are approved with these purposes. These agents
allow rapid absorption and quick onset of effect, with good
levels of acceptability to patients [5]. In some conditions, oral
mucosa may be damaged and drug absorption may be prob-
lematic. A possible alternative approach to the treatment of
BTP is to take advantage of the favorable absorption and
characteristics of the nasal mucosa, which allows for rapid
drug absorption and, hence, rapid onset of analgesia [6].
Intranasal fentanyl (INFS) is a treatment option approved
for the management of BTP in adult cancer patients already
receiving maintenance opioid therapy for chronic cancer pain.
INFS has been used in various settings, populations, and
different circumstances [6–36]. Clinical studies in cancer pa-
tients have shown that INFS provides clinically relevant re-
ductions in pain intensity [37], with superior efficacy and
patient preference, compared to oral transmucosal fentanyl
citrate (OTFC) [38]. Previous evaluations of INFS were con-
ducted through controlled clinical trials. From a systematic
literature review, INFS is expected to provide the greatest
improvement in the treatment of BTP [39]. The aim of the
present study was to assess the long-term tolerability and
efficacy of INFS in opioid-tolerant patients with BTP.
Patients and methods
A non-interventional, 6 months, observational, prospective,
cohort study design was employed to follow advanced cancer
patients with BTP receiving INFS under routine clinical prac-
tice. The study was conducted according to the Declaration of
Helsinki and Ethics Committees granted ethical approval.
Study participation had no impact on the patient (except for
the collection of informed consent, requested after the treat-
ment decision); the decision to prescribe INFS had been
determined as part of current practice. Patients were not sub-
jected to additional procedures; participating study physicians
were responsible for all decisions regarding patient care.
Eligible patients were adult cancer patients (home care or
outpatients) suffering from BTP who had been prescribed
INFS at effective doses. All patients provided informed con-
sent for the collection of data prior to study inclusion. Adult
cancer patients (aged ≥18 years) with stable cancer related
pain were recruited into the study. A convenience sample of
patients using INFS for three consecutive days effectively was
surveyed for a follow-up of six months.
Inclusion criteria were patients with receiving opioids for
background pain and having episodes of BTP treated with
INFS, a well-controlled background pain while receiving a
fixed-schedule oral opioid regimen of ≥60 oral morphine
equivalents of different opioids (less than 4/10 of pain inten-
sity on a numerical scale from 0 to 10), 1–3 episodes of BTP
per day, and an expected survival of greater than 6 months
Exclusion criteria included uncontrolled or rapidly escalat-
ing pain, any clinically significant condition that would, in the
investigator’s opinion, precluded study participation or in-
crease the risk of administering potent opioids, the use of
monoamine oxidase inhibitors within 14 days, or other anti-
cancer interventions with a potential to interfere with the
treatment, patients severely ill.
Patients were recruited from four study centers across Italy.
Data were collected at T0 and at month intervals for six
months (T1 to T6). In case of need, visits or phone contacts
were anticipated. Data were mainly obtained from source data,
by the investigator, and were collected for INFS-treated pa-
tients only. The trend of INFS doses in timewas also recorded.
Adverse reactions were recorded, with an intensity graded
from 0 to three (absence, mild, moderate, and severe). Effica-
cy was based on a general impression regarding the efficacy of
INFS with the following scale: 1 (poor), 2 (acceptable), 3
(good), 4 (very good), 5 (excellent). [42]. Quality of sleep
was rated with the following scale: 0 (disturbed), 1 (frequent
arousals), 2 (good), 3 (very good).
The principal outcomes were the evaluation of possible
serious adverse effects with prolonged use of INFS, the effi-
cacy of BTP treatment with INFS, the quality of sleep, the rate
of INFS discontinuation, and reasons for that. Secondary
outcomes were the relationship with the dose of INFS and
opioid doses used for background analgesia commonly
changed to maintain an acceptable background pain (≤4/10
on a numerical scale 0–10).
Statistical analysis
Data were analyzed by the IBM SPSS Software 21.0 version
(SPSS, Inc., Chicago, Ill, US) and the Epi Info software,
version 3.2.2, (Centers for Disease Control and Prevention).
Statistical analysis of quantitative and qualitative data, includ-
ed descriptive statistics, was performed for all the items.
Frequency analysis was performed with chi-square test. The
paired Wilcoxon signed-rank test and ANOVA test for
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repeated measures were used to compare non-parametric and
parametric variables, respectively, at different intervals.
Pearson’s correlation test was used to test for a comparison
between opioids doses, expressed as oral morphine equiva-
lents (OME) and doses of INFS. All P values were two-sided,
and P values less than 0.05 were considered to indicate
statistical significance.
Results
Seventy-five patients were surveyed. Thirty-four patients
(45.3 %) had a follow-up at 3 months, and twelve patients
(16 %) were followed up at 6 months. The characteristics of
patients are described in Table 1. Seven patients dropped out
at T1: one patient died and six were unavailable. Eleven
patients dropped out at T2: six patients died, one was unavail-
able, and four were lost in the follow-up. Twenty-three pa-
tients dropped out at T3: 17were unavailable and six were lost
in the follow-up. Seven patients dropped out at T4: two
patients died and five patients were unavailable. Eight patients
dropped out at T5: six died and two were unavailable. Finally,
seven patients dropped out at T6: two patients died, two were
unavailable, and three were lost in the follow-up. No patient
discontinued the treatment for severe adverse effects, and no
aberrant drug-related behavior was observed.
Opioids and doses, expressed as oral morphine equivalents
(OME) given for background analgesia, and doses of INFS
are reported in Table 2. Mean opioid doses ranged 111–
180 mg/day, while the mean INFS doses were 87–119 μg.
Doses of INFS and OMR significantly increased in time,
unless some certain time intervals, possibly due to a lower
number of patients continuing the study at months 5 and 6.
There was a statistical correlation between INFS and OME
doses at T0 and T1 (Pearson correlation coefficient 0.545,
P<0.0005, and 0.248, P=0.043, respectively), but not at the
subsequent time intervals.
Adverse effects were reported in a minority of patients and
were considered to be associated with opioid therapy used for
background pain. The intensity was mild and only few pa-
tients presented symptoms of moderate intensity (Table 3).
The quality of sleep significantly improved during the first
3–4 months (Table 4). Finally, efficacy based on a general
impression regarding the efficacy of INFS was good-excellent
in most patients and statistically improved in time up to the
third month (Table 5).
Discussion
This long-term study in advanced cancer patients with BTP
has shown that INFS was well tolerated for prolonged periods
of time and was effective in controlling episodes of BTP,
according to the general impression reported by patients.
Adverse effects were of mild-moderate intensity and mostly
attributed to opioids administered for background pain. Qual-
ity of sleep was relatively maintained in time, and no
Table 1 Patients’ demographics and baseline characteristics
Mean age, years (SD) 64.8 (12.7)
Male, n (%) 65 (86.7)
Karnofsky 69.9 (26.3)
Site of primary tumor, n (%) n (%)
Lung/respiratory 16 (21.3)
Colon/rectum 13 (17.3)
Breast 18 (24.0)
Head and neck 6 (8.1)
Urogenital 13 (17.3)
Pancreas 1 (1.3)
Liver 3 (4)
Others 5 (6.7)
Table 2 Number of patients using the different opioids, mean oral morphine equivalents (OME) (SD), and mean INFS dose (SD) at the different time
intervals
T0 T1 T2 T3 T4 T5 T6
N° pts 75 68 57 34 27 19 12
TD buprenorphine 5 3 1 1 1 – –
TD Fentanyl 18 17 14 8 8 8 5
Morphine 12 12 9 7 4 3 2
Hydromorphone 6 3 1 – – – –
Oxycodone 28 25 23 16 12 7 4
Tapentadol 5 5 5 – – – –
Methadone 2 1 1 1 1 1 1
OME (mg) 121 (106) 122 (92) 138 (106)* 111 (105) 138 (112)* 142 (132) 180 (181)
INFS (μg) 87 (70) 90 (49)* 113 (63)* 103 (75)* 108 (82) 119 (94) 100 (59)
*P<0.05 versus T0
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discontinuation of treatment was due to INFS-related adverse
effects. Rather, drop-out rate was relatively expected, due to
the nature of the study assessing advanced cancer patients
with a limited survival. Finally, no aberrant drug-related be-
havior was observed.
Many cancer patients are managed for prolonged periods of
time and treatment of BTPmay last several months. Therefore,
it is of paramount importance to gather information about the
long-term use of medications commonly used for BTP. Data
regarding long-term use of second generation fentanyl prod-
ucts in cancer patients are limited. A series of extension studies
of previous controlled studies have shown that fentanyl prod-
ucts are well tolerated and effective. Fentanyl buccal tablet
(FBT) waswell tolerated and had a favorable safety profile in a
long-term (up to 12 months) management of BTP. Adverse
effects were unrelated to study drug [40]. Subsequently, FBT
has been assessed for 12 weeks in an open-label extension
phase after completing a controlled study with oral opioids in
both cancer and non-cancer patients. Most adverse effects
were attributed to opioids given for background pain or were
of minor intensity. Only one patient discontinued the treat-
ment, due to a withdrawal syndrome after stopping to take
opioids. A better functional improvement and satisfaction with
FBT vs short acting opioids were reported [41]. Sublingual
fentanyl (SLF) was assessed in cancer patients in a long-term
safety phase of 12 months for the management of BTP. Only
one patient dropped out for a serious adverse effect considered
as possibly related to study medication [42].
The long-term tolerability, efficacy, and acceptability of fen-
tanyl pectin spray (FPNS) for BTP has been recently reported in
a 16 weeks period. FPNS was generally well tolerated and
accepted by patients, and adverse effects were of mild to mod-
erate intensity. One third of patients completed 16 weeks of
treatment. Nine patients discontinued for adverse effects due to
the study drug. Severe local damage was reported in one patient
[43]. In a subsequent extension study, the need of discontinuation
of FPNS was not related to the drug, and only one patient who
misused the drug had serious adverse effects [44]. One study
assessed INFS for three months. One-third of patients were still
receiving INFS at the end of the study. Serious adverse effects
were reported in about 3 % of patients who discontinued INFS.
Other than death, discontinuation occurred for lack of efficacy or
other reasons. The treatment improved patients’ satisfaction and
brief pain inventory from baseline to the fourth week [45].
Of interest, in almost these studies, the effective dose was
achieved after an open-label phase of dose titration of about
two weeks, although most patients were administered the
lowest strengths. After performing a controlled phase, they
entered an extension phase. The majority of patients main-
tained the doses to which they were titrated throughout their
participation in the study.When available, the doses of opioids
used for background pain was unchanged.
Differently from the findings reported in these studies, in
the present long-term study of INFS, physicians could use
either dose titration or doses proportional to the opioid basal
Table 3 Number of patients (%) presenting adverse effects of mild-moderate intensity at different time intervals (above) and number of patients (below)
presenting specific adverse effects with a moderate intensity
T0 T1 T2 T3 T4 T5 T6
N° pts 75 68 57 34 27 19 12
Adverse effects, n (%) 21 (28) 28 (41) 24 (42) 14 (41) 11 (41) 7 (37) 3 (25)
Symptoms with moderate intensity
All 2 (2.7) 15 (22) 3 (5.3) 1 (2.9) 3 (11.1) 1 (5.2) 0 (0.0)
Headache 1 (1.4) 1 (1.7)
Drowsiness 1 (1.3) 11 (16)
Constipation 1 (1.3) 2 (2.9) 2 (3.5) 1 (2.9) 2 (7.4) 1 (5.2)
Dizziness 1 (1.4) 1 (3.7)
Table 4 Levels of quality of sleep at the different intervals
T0 T1 T2 T3 T4 T5 T6
N° pts 75 68 57 34 27 19 12
Sleep scores 1 2 12 7 2 3 3 2
2 16 28 26 9 5 4 5
3 25 28 24 23 19 12 5
4 32 – – – – – –
P .0005 .0005 .0005 .043 .103 .287
Table 5 Distribution of patients according to the INFS efficacy
T0 T1 T2 T3 T4 T5 T6
N° pts 75 68 57 34 27 19 12
Efficacy score 1 – – 1 1 – – –
2 11 5 2 – – 2 –
3 14 16 15 2 – 2 2
4 27 25 19 15 9 7 5
5 23 22 20 16 18 8 5
P .0005 .0005 .063 .357 .440 .766
1352 Support Care Cancer (2015) 23:1349–1354
regimen for dosing INFS and doses were then changed ac-
cording to the clinical need. Increases in time of both opioid
doses for background pain and INFS doses were limited. A
dose correlation was found for the first month, and disap-
peared at the subsequent time intervals, possibly because of
the decrease in the number of patients who were continuing
the study. On average, there was a proportion between the
mean OME and INFS doses (111–180 mg/day, and 87–
119 μg, respectively). It has been shown that INFS and FPNS
in doses proportional to basal opioid regimen are equally safe
and effective for the management of breakthrough pain in
cancer patients. These data provide new insights on the use
of nasal preparations of fentanyl [46].
The treatment was effective and able to maintain sleep
quality at acceptable levels, rather than being particularly
accepted by patients who were particularly satisfied with the
treatment. Most of patients discontinued the treatment for
death or unavailability to continue study participation, and
about half of patients dropped out from the study. This finding
was expected and reflects the underlying disease states of
patients and the long duration of the trial. No patient
discontinued the study drug for serious adverse effects, which
were mild-moderate in intensity and attributed to background
opioids or the underlying disease.
There are limitations to consider, which are inherent with
studies in advanced cancer patients. Patient numbers were low
after some weeks, due to a physiological drop-out percentage,
typical of a cohort of patients with progressive disease or
unavailability of patients to maintain the contact with the
study center. No comparator arm was used. However, this
approach was deemed to not have contributed to the objective
of the description of the study, which regarded the safety and
efficacy of INFS in a real clinical world. The treatment was
changed according to the clinical need, without restricted
obligations of a protocol. Indeed, this reflects the real life of
advanced cancer patients.
In conclusion, this long-term study has shown that the use
of INFS in advanced cancer patients is effective and safe. No
serious adverse effects were found up to six months of assess-
ment. Doses of opioids used for background analgesia and
INFS doses may be changed according to clinical needs, as
expected in advanced cancer patients. The level of quality of
sleep and patients’ satisfaction was relatively good, consider-
ing the advanced stage of disease, although a multitude of
factors may have an influence. Other studies on large scale
should confirm the safety and efficacy of fentanyl products for
the management of BTP.
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